Localized and systemic scleroderma

Seminars in Cutaneous Medicine and Surgery

Volumn 20, Issue 1, 2001, Pages 27-37

  Hawk, A ^a   English III, J C ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; PATHOGENESIS; PREVALENCE; PROGNOSIS; RAYNAUD PHENOMENON; REVIEW; SYSTEMIC SCLEROSIS;

EID: 0035076057     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1053/sder.2001.23093     Document Type: Review

References (55)

1. Scleroderma and related conditions
2. Guidelines of care for scleroderma and sclerodermoid disorders
3. Morphea and localized scleroderma in children
4. Preliminary criteria for the classification of systemic sclerosis (scleroderma)
5. Classification and epidemiology of scleroderma
6. The epidemiology of morphea (localized scleroderma) in Olmstead Country, 1960-1993
7. Scleroderma
8. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States
9. Racial differences in scleroderma among women in Michigan
10. Systemic sclerosis prevalence and mortality in Sydney 1974-88
11. Geographical clustering of mortality from systemic sclerosis in the Southeastern United States, 1981-90
12. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype
13. Management of localized scleroderma
14. Systemic sclerosis (scleroderma)
15. Mechanism of serum-mediated endothelial injury in scleroderma: Identification of a granular enzyme in scleroderma skin and sera
16. Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): Association with pulmonary fibrosis
17. ET-1 plasma levels during cold stress test in sclerodermic patients
18. Abnormalities of adhesion molecules and chemokines in scleroderma
19. Serologic abnormalities in systemic sclerosis
20. Role of metal-catalyzed oxidation reactions in early pathogenesis of scleroderma
21. Biology of the scleroderma fibroblast
22. Microchimerism and the pathogenesis of systemic sclerosis
23. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum
24. Systemic sclerosis from autoimmunity to alloimmunity
25. Familial risk estimation in systemic sclerosis
26. Association of microsatellite markers near the fibrillin 1 gene on human chromosome 15q with scleroderma in a Native American population
27. Localized scleroderma
28. Eosinophilia-myalgia syndrome, eosinophilic fasciitis, and related fibrosing disorders
29. Clinical manifestations of systemic sclerosis
30. Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis
31. Topical calcipotriene for morphea/linear scleroderma
32. Double-blind, placebo-controlled study of intralesional interferon gamma for the treatment of localized scleroderma
33. D-penicillamine in the treatment of localized scleroderma
34. Low-dose methotrexate in the treatment of widespread morphea
35. Low-dose UVA1 phototherapy for treatment of localized scleroderma
36. PUVA bath photochemotherapy for localized scleroderma. Evaluation of 17 consecutive patients
37. Psoralen UVA therapy for linear and generalized morphea
38. Topical photodynamic therapy for localized scleroderma
39. Management of systemic sclerosis: The art and the science
40. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis
41. Cyclosporin A and iloprost treatment of systemic sclerosis: Clinical results and interleukin-6 serum changes after 12 months of therapy
42. Advances in the treatment of systemic sclerosis
43. Clinical approach to scleroderma
44. Recombinant human relaxin in the treatment of scleroderma: A randomized, double-blind, placebo-controlled trial
45. Interferon-gamma in the treatment of systemic sclerosis: A randomized controlled multicenter trial
46. Systemic scleroderma: Multicenter trial of 1 year of treatment with recombinant interferon gamma
47. Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photophoresis)
48. Minocycline in early diffuse scleroderma
49. Development of a protocol for allogenic marrow transplantation for severe systemic sclerosis: Paradigm for autoimmune disease
50. Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation
51. Mortality and causes of death in a Swedish series of systemic sclerosis patients
52. Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma)
53. Prediction of five-year survival following presentation with scleroderma: Development of a simple model using three disease factors at first visit
54. Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis